Capital International Inc. CA Sells 20,136 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital International Inc. CA decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 16.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,085 shares of the biopharmaceutical company's stock after selling 20,136 shares during the period. Capital International Inc. CA owned 0.08% of Alnylam Pharmaceuticals worth $24,728,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ALNY. MML Investors Services LLC lifted its position in shares of Alnylam Pharmaceuticals by 5.7% during the third quarter. MML Investors Services LLC now owns 3,086 shares of the biopharmaceutical company's stock worth $849,000 after purchasing an additional 166 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 4,558 shares of the biopharmaceutical company's stock worth $1,254,000 after buying an additional 2,181 shares in the last quarter. Tidal Investments LLC boosted its position in Alnylam Pharmaceuticals by 75.1% in the 3rd quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company's stock valued at $5,650,000 after buying an additional 8,811 shares during the last quarter. American Trust acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $309,000. Finally, Versant Capital Management Inc raised its position in shares of Alnylam Pharmaceuticals by 77.6% during the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 1.8 %

Alnylam Pharmaceuticals stock opened at $234.56 on Friday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company's 50-day moving average is $249.14 and its 200-day moving average is $257.07. The firm has a market capitalization of $30.51 billion, a PE ratio of -108.09 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 over the last 90 days. Insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ALNY. Chardan Capital reiterated a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Needham & Company LLC restated a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Finally, Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.